{"id":"rituximab-iv","safety":{"commonSideEffects":[{"rate":"null","effect":"Infusion reactions"},{"rate":"null","effect":"Infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Rituximab IV is a monoclonal antibody that binds to the CD20 antigen on the surface of B cells, leading to their depletion through mechanisms including complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. This results in a reduction in B cell-mediated inflammation and immune responses.","oneSentence":"Rituximab IV works by targeting and depleting CD20-positive B cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:33:52.126Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin's lymphoma"},{"name":"Chronic lymphocytic leukemia"}]},"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":"Primary Mediastinal Large B-Cell Lymphoma","enrollment":244},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":"Lymphoma","enrollment":129},{"nctId":"NCT05139017","phase":"PHASE2, PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":"DLBCL, Diffuse Large B-Cell Lymphoma","enrollment":290},{"nctId":"NCT06965114","phase":"PHASE1, PHASE2","title":"Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-27","conditions":"Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia","enrollment":84},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT05886036","phase":"PHASE2","title":"Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-23","conditions":"Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma","enrollment":70},{"nctId":"NCT04840602","phase":"PHASE2","title":"Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-01-05","conditions":"Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia","enrollment":92},{"nctId":"NCT01886872","phase":"PHASE3","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-15","conditions":"Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia","enrollment":547},{"nctId":"NCT03321643","phase":"PHASE1","title":"Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-18","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":24},{"nctId":"NCT07494565","phase":"PHASE2","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-05","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL), CD5 Positive","enrollment":60},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":"Lymphoma","enrollment":95},{"nctId":"NCT02160015","phase":"PHASE1","title":"Lenalidomide, Ibrutinib, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Is Metastatic or Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-20","conditions":"Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia","enrollment":12},{"nctId":"NCT03984448","phase":"PHASE2, PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":"Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma","enrollment":363},{"nctId":"NCT06337318","phase":"PHASE3","title":"Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-10-23","conditions":"Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features","enrollment":600},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":"Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":349},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":1046},{"nctId":"NCT01695941","phase":"PHASE1","title":"Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2012-08-31","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma","enrollment":24},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":"Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell Lymphoma","enrollment":16},{"nctId":"NCT01829568","phase":"PHASE1","title":"Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-06-26","conditions":"Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma","enrollment":33},{"nctId":"NCT02682641","phase":"PHASE2","title":"Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea","startDate":"2016-05-18","conditions":"Mantle Cell Lymphoma","enrollment":50},{"nctId":"NCT04609046","phase":"PHASE1","title":"Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-24","conditions":"Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System","enrollment":47},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":50},{"nctId":"NCT01842386","phase":"PHASE1","title":"Rituximab for Anti-cytokine Autoantibody-Associated Diseases","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-04-29","conditions":"Pulmonary Alveolar Proteinosis (PAP), Severe Mucocutaneous Candidiasis","enrollment":7},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":"Follicular Lymphoma (FL)","enrollment":109},{"nctId":"NCT02446236","phase":"PHASE1","title":"Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2015-06-18","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":"B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1, Lymphoblastic Lymphoma","enrollment":33},{"nctId":"NCT06821542","phase":"PHASE3","title":"A Study to Evaluate Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Corporation","startDate":"2025-06-04","conditions":"Chronic Graft-versus-host-disease","enrollment":9},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":"Liver Lymphoma, Mantle Cell Lymphoma","enrollment":360},{"nctId":"NCT04799275","phase":"PHASE2, PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":"Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","enrollment":422},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT01479842","phase":"PHASE1","title":"Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kami Maddocks, MD","startDate":"2014-03-26","conditions":"Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma","enrollment":48},{"nctId":"NCT05025800","phase":"PHASE1, PHASE2","title":"ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-13","conditions":"Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma","enrollment":47},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":"Lymphoma, Large B-Cell, Diffuse","enrollment":594},{"nctId":"NCT07226843","phase":"PHASE1","title":"A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers","status":"NOT_YET_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2026-02","conditions":"Lymphoma, Non-Hodgkin's, Lymphoma, Diffuse Large B-Cell, Follicular Lymphoma","enrollment":360},{"nctId":"NCT04458610","phase":"PHASE2","title":"Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-26","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":60},{"nctId":"NCT02405676","phase":"PHASE2, PHASE3","title":"BNHL-2015 for Children or Adolescents in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2015-01-01","conditions":"Mature B-cell Non-Hodgkin Lymphoma","enrollment":200},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT06561360","phase":"PHASE2","title":"A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-09","conditions":"Hairy Cell Leukemia","enrollment":86},{"nctId":"NCT06047080","phase":"PHASE3","title":"An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-09-18","conditions":"Large B-Cell Lymphoma","enrollment":1130},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT07477366","phase":"PHASE2","title":"Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2026-04","conditions":"Relapsed B-Cell Non-Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT06918431","phase":"PHASE2","title":"Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-10-10","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic Lymphoma","enrollment":53},{"nctId":"NCT04404283","phase":"PHASE3","title":"Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seagen, a wholly owned subsidiary of Pfizer","startDate":"2020-08-20","conditions":"Diffuse Large B-cell Lymphoma","enrollment":238},{"nctId":"NCT01679119","phase":"PHASE2","title":"Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy","status":"COMPLETED","sponsor":"University College, London","startDate":"2013-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":129},{"nctId":"NCT00006721","phase":"PHASE3","title":"S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"SWOG Cancer Research Network","startDate":"2001-03","conditions":"Lymphoma","enrollment":571},{"nctId":"NCT07125872","phase":"PHASE2","title":"Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma","status":"RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2025-11-11","conditions":"Relapsed B-Cell Non Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":300},{"nctId":"NCT06931652","phase":"PHASE2","title":"Study of Epcoritamab in R/R Primary Diffuse Large B-cell Lymphoma of the CNS Treated With Lenalidomide and Rituximab","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2025-09-22","conditions":"Primary CNS Lymphoma (PCNSL)","enrollment":60},{"nctId":"NCT03523975","phase":"PHASE1, PHASE2","title":"Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2018-12-24","conditions":"Mantle Cell Lymphoma","enrollment":28},{"nctId":"NCT05947851","phase":"PHASE3","title":"A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-08-08","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma","enrollment":735},{"nctId":"NCT06572618","phase":"PHASE2","title":"Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2025-01-22","conditions":"Mantle Cell Lymphoma","enrollment":27},{"nctId":"NCT06738368","phase":"PHASE2","title":"Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-01","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT04644016","phase":"PHASE2","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-11-20","conditions":"AML, ALL, MDS","enrollment":31},{"nctId":"NCT05683171","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-05-19","conditions":"Lymphoma","enrollment":60},{"nctId":"NCT05453500","phase":"PHASE2","title":"Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"University of Washington","startDate":"2023-03-27","conditions":"B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative","enrollment":30},{"nctId":"NCT00492050","phase":"PHASE2","title":"Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-08-02","conditions":"Waldenstrom's Macroglobulinemia","enrollment":46},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT07104032","phase":"PHASE3","title":"IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)","status":"RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2026-03","conditions":"Relapsed/Refractory Primary Central Nervous System Lymphoma","enrollment":132},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":590},{"nctId":"NCT07350850","phase":"PHASE2","title":"A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-12-25","conditions":"PCNSL, Primary Central Nervous System Lymphoma","enrollment":110},{"nctId":"NCT02446457","phase":"PHASE2","title":"Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma","enrollment":53},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT04075292","phase":"PHASE3","title":"Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-01-20","conditions":"Untreated Chronic Lymphocytic Leukemia","enrollment":155},{"nctId":"NCT02339922","phase":"PHASE2","title":"Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2016-05-19","conditions":"Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma","enrollment":33},{"nctId":"NCT07451847","phase":"PHASE4","title":"Comparison of a Strategy Based on Clinico-biological Monitoring Versus Pre-emptive Rituximab Treatment in Cases of ANCA Reappearance in Granulomatosis With Polyangiitis and Microscopic Polyangiitis.","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-02","conditions":"ANCA Associated Vasculitis (AAV), Polyangiitis (GPA), Microscopic Polyangiitis (MPA)","enrollment":70},{"nctId":"NCT05800366","phase":"PHASE2","title":"A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Jennifer Crombie, MD","startDate":"2023-04-06","conditions":"Lymphoma, Lymphoma, Large B-Cell, Diffuse","enrollment":41},{"nctId":"NCT04216524","phase":"PHASE2","title":"Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-05-29","conditions":"Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":40},{"nctId":"NCT07294677","phase":"PHASE1, PHASE2","title":"CApivasertib, Venetoclax And Low-intensity chemotheRapY for Adults With ALL/LBL","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2026-03-17","conditions":"Leukemia, Lymphoma","enrollment":104},{"nctId":"NCT05976763","phase":"PHASE3","title":"Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2023-10-20","conditions":"Mantle Cell Lymphoma","enrollment":421},{"nctId":"NCT07137481","phase":"PHASE2","title":"Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2027-02-28","conditions":"Hematological Malignancies","enrollment":70},{"nctId":"NCT05283720","phase":"PHASE2","title":"A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2022-06-14","conditions":"Non-Hodgkin Lymphoma","enrollment":496},{"nctId":"NCT03789240","phase":"PHASE2","title":"Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-22","conditions":"Follicular Lymphoma, Non-Hodgkin's Lymphoma, NHL","enrollment":33},{"nctId":"NCT04231877","phase":"PHASE1","title":"Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2020-10-27","conditions":"Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","enrollment":56},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":"Chronic Lymphocytic Leukemia (CLL)","enrollment":166},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":"Follicular Lymphoma (FL)","enrollment":1095},{"nctId":"NCT06508658","phase":"PHASE3","title":"A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-08-13","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":360},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":"Lymphoma","enrollment":182},{"nctId":"NCT05605899","phase":"PHASE3","title":"Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2023-02-10","conditions":"High-risk Large B-cell Lymphoma (LBCL)","enrollment":300},{"nctId":"NCT06364423","phase":"PHASE1, PHASE2","title":"Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-03","conditions":"Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia","enrollment":132},{"nctId":"NCT06522386","phase":"PHASE2","title":"GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-01-30","conditions":"Mantle Cell Lymphoma","enrollment":40},{"nctId":"NCT03150693","phase":"PHASE3","title":"Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia","status":"SUSPENDED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2017-09-20","conditions":"B Acute Lymphoblastic Leukemia","enrollment":310},{"nctId":"NCT04224493","phase":"PHASE3","title":"A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.","status":"RECRUITING","sponsor":"Epizyme, Inc.","startDate":"2020-06-11","conditions":"Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma","enrollment":612},{"nctId":"NCT06504940","phase":"PHASE2","title":"Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-28","conditions":"Marginal Zone Lymphoma","enrollment":69},{"nctId":"NCT06209619","phase":"PHASE1","title":"CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Nathan Denlinger","startDate":"2024-01-29","conditions":"B-Cell Non-Hodgkin Lymphoma-Recurrent, Diffuse Large B-Cell Lymphoma-Recurrent, Follicular Lymphoma-Recurrent","enrollment":18},{"nctId":"NCT07257055","phase":"PHASE2","title":"Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-12","conditions":"Phase 2 Study, MCL, BTKi","enrollment":30},{"nctId":"NCT06045247","phase":"PHASE2","title":"Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-05","conditions":"Large B-cell Lymphoma","enrollment":40},{"nctId":"NCT06078696","phase":"PHASE1, PHASE2","title":"Siplizumab for Sickle Cell Disease Transplant","status":"TERMINATED","sponsor":"Columbia University","startDate":"2023-09-28","conditions":"Anemia, Sickle Cell","enrollment":1},{"nctId":"NCT04268277","phase":"PHASE2","title":"Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY","status":"TERMINATED","sponsor":"University of Ulm","startDate":"2022-03-01","conditions":"Marginal Zone Lymphoma","enrollment":22},{"nctId":"NCT01473628","phase":"PHASE1, PHASE2","title":"Radiation Therapy and Rituximab in Treating Patients With Stage I-II Grade 1 or Grade 2 Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-05-20","conditions":"Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Follicular Lymphoma","enrollment":81},{"nctId":"NCT05495464","phase":"EARLY_PHASE1","title":"A Pilot \"Window-3\" Study of Acalabrutinib Plus Rituximab Followed by Brexucabtagene Autoleucel Therapy in Patients With Previously Untreated High-risk Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-11-18","conditions":"Lymphoma, Mantle Cell Lymphoma","enrollment":22},{"nctId":"NCT06651970","phase":"PHASE4","title":"Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-02-04","conditions":"Chronic Lymphocytic Leukaemia, Heart Failure","enrollment":60},{"nctId":"NCT03394365","phase":"PHASE3","title":"A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2017-12-29","conditions":"Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders","enrollment":115},{"nctId":"NCT04421560","phase":"PHASE1, PHASE2","title":"Pembrolizumab, Ibrutinib and Rituximab in PCNSL","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-08-01","conditions":"Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer","enrollment":37},{"nctId":"NCT04554914","phase":"PHASE2","title":"A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases","status":"RECRUITING","sponsor":"Pierre Fabre Medicament","startDate":"2021-07-14","conditions":"Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)","enrollment":190},{"nctId":"NCT04002947","phase":"PHASE2","title":"Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-05","conditions":"Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, DLBCL","enrollment":132},{"nctId":"NCT05389423","phase":"PHASE1","title":"Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-06-27","conditions":"Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma","enrollment":25},{"nctId":"NCT03929601","phase":"PHASE2","title":"Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2023-10-30","conditions":"Type 1 Diabetes Mellitus","enrollment":74},{"nctId":"NCT01880567","phase":"PHASE2","title":"Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-07-15","conditions":"CCND1 Positive, CCND2 Positive, CCND3 Positive","enrollment":113},{"nctId":"NCT04745949","phase":"PHASE2","title":"PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-05-10","conditions":"Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":31}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":15,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MabThera","Mabthera","MabThera IV"],"phase":"phase_3","status":"active","brandName":"Rituximab IV","genericName":"Rituximab IV","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rituximab is an antibody that binds to the B-lymphocyte antigen CD20, classified as a binding agent. It is used to treat conditions such as Non-Hodgkin's Lymphoma, DLBCL, and Graft vs Host Disease, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}